CompletedNot Applicable

A Study to Evaluate the Safety and Efficacy of Restylane Defyne for Chin Augmentation and Correction of Chin Retrusion

United States140 participantsStarted 2018-08-21

Plain-language summary

To demonstrate the effectiveness of Restylane Defyne for chin augmentation and correction of chin retrusion by demonstrating the superiority in responder rates relative to no treatment.

Who can participate

Age range22 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects willing to comply with the requirements of the study and providing a signed written informed consent. * Males or non-pregnant, non-breastfeeding females, 22 years of age or older, seeking chin augmentation or correction of retrusion Exclusion Criteria: * Allergy of hypersensitivity to any injectable hyaluronic acid gel or to gram positive bacterial proteins * Allergy or hypersensitivity to lidocaine or other amide-type anesthetics, or topical anesthetics or nerve blocking agents

What they're measuring

Evaluate Effectiveness of the Treatment Using the Galderma Chin Restrusion Scale

Timeframe: 12 weeks after baseline

Trial details

NCT IDNCT03624816

SponsorGalderma R&D

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-03-07

Results submitted2021-03-22

View on ClinicalTrials.gov More Chin Retrusion trials